|
|
| | Tocainide hydrochloride Basic information |
| Product Name: | Tocainide hydrochloride | | Synonyms: | 2-amino-n-(2,6-dimethylphenyl)propanamide hydrochloride;tocainide hydrochloride;2-amino-n-(2,6-dimethylphenyl)propanamidemonohydrochloride;2-amino-n-(2,6-dimethylphenyl)-propanamidmonohydrochloride;tonocardhydrochloride;TOCAINIDE HCL;Propanamide, 2-amino-N-(2,6-dimethylphenyl)-, monohydrochloride;Unii-2K7I38ckn5 | | CAS: | 35891-93-1 | | MF: | C11H17ClN2O | | MW: | 228.71848 | | EINECS: | | | Product Categories: | | | Mol File: | 35891-93-1.mol |  |
| | Tocainide hydrochloride Chemical Properties |
| Melting point | 244-245°C | | storage temp. | -20°C Freezer | | solubility | Methanol (Slightly), Water (Slightly) | | form | Solid | | color | Off-White |
| | Tocainide hydrochloride Usage And Synthesis |
| Uses | Tonocard(AstraZeneca). | | Uses | Tocainide Hydrochloride is used as an anti-arrythmic drug as myocardial depressants. | | General Description | Tocainide hydrochloride,2-amino-2＇ ,6 ＇-propionoxyxylidide hydrochloride (Tonocard)(pKa 7.7), is an analog of lidocaine. It is orally active and haselectrophysiological properties like those of lidocaine. Totalbody clearance of tocainide hydrochloride is only166 mL/min, suggesting that hepatic clearance is not large.Because of low hepatic clearance, the hepatic extraction ratiomust be small; therefore, tocainide hydrochloride is unlikelyto be subject to a substantial first-pass effect. The drug differsfrom lidocaine, in that it lacks two ethyl groups, which providestocainide hydrochloride some protection from first-passhepatic elimination after oral ingestion. Tocainide hydrochlorideis hydrolyzed in a manner similar to that of lidocaine.None of its metabolites is active. | | Clinical Use | Tocainide hydrochloride is classed as a IB antiarrhythmicagent and used orally to prevent or treat ventricular ectopyand tachycardia. The drug is given in 400- to 600-mgdoses every 8 hours. | | Veterinary Drugs and Treatments | Veterinary experience with tocainide is limited. At this time, dogs
are the only veterinary species where enough clinical experience has
been garnered to recommend its use. It is indicated for the oral therapy
of ventricular arrhythmias, principally ventricular tachycardia
and ventricular premature complexes. In humans, response to lidocaine
can usually predict whether tocainide might be effective. |
| | Tocainide hydrochloride Preparation Products And Raw materials |
|